Carl Zeiss Meditec AGXSWX:AFX 70 Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 70/100 and a GF Value™ of CHF64.87 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 66.24% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Carl Zeiss Meditec AG's Debt-to-EBITDA or its related term are showing as below:
XSWX:AFX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.26 Max: 0.68
Current: 0.68
During the past 13 years, the highest Debt-to-EBITDA Ratio of Carl Zeiss Meditec AG was 0.68. The lowest was 0.03. And the median was 0.26.
XSWX:AFX's Debt-to-EBITDA is ranked better than 66.24% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs XSWX:AFX: 0.68
Carl Zeiss Meditec AG (XSWX:AFX) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Carl Zeiss Meditec AG Debt-to-EBITDA Related Terms
Carl Zeiss Meditec AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:AFX vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Carl Zeiss Meditec AG (XSWX:AFX) has a Debt-to-EBITDA of 0.00 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Carl Zeiss Meditec AG. Over the past decade, Carl Zeiss Meditec AG's Debt-to-EBITDA has ranged from 0.03 to 0.68. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #158 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 33.8%.
Is Carl Zeiss Meditec AG's Debt-to-EBITDA too high?
Carl Zeiss Meditec AG's current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.68. Based on the distribution chart, Carl Zeiss Meditec AG ranks #158 out of 468 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #158 out of 468 companies for Debt-to-EBITDA. This puts Carl Zeiss Meditec AG in the upper half of its industry. The industry median Debt-to-EBITDA is 1.56. Historically, Carl Zeiss Meditec AG's own Debt-to-EBITDA has ranged from 0.03 to 0.68 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Carl Zeiss Meditec AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF64.87, compared to a current price of CHF25.86 — trading 60.1% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF25.86 is trading 60.1% below its estimated GF Value™ of CHF64.87.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
Debt-to-EBITDA: 0.00
GF Value™: CHF64.87 vs. price of CHF25.86 (60.1% below fair value)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score
Get the complete analysis for XSWX:AFX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
